QURE News

Pomerantz LLP Shares Class Action Details With Investors in uniQure N.V. – QURE

QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data

QURE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 Ready to Announce with Confidence?

uniQure N.V. (QURE) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP

Levi & Korsinsky Reminds uniQure N.V. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 13, 2026 - QURE

QURE Investors Have Opportunity to Lead uniQure N.V. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!

Pomerantz LLP Reminds Investors: Securities Lawsuit Has Been Filed Against uniQure N.V. – QURE

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed; April 13, 2026, Lead Plaintiff Deadline

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE